Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report published on Sunday morning. The brokerage issued a hold rating on the stock.

ONCT has been the topic of several other research reports. Northland Capmk downgraded Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Northland Securities reiterated a “market perform” rating and issued a $2.00 target price on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Oncternal Therapeutics currently has an average rating of “Hold” and a consensus price target of $10.00.

Oncternal Therapeutics Price Performance

Shares of NASDAQ ONCT opened at $0.53 on Friday. The firm’s 50-day moving average price is $0.98 and its two-hundred day moving average price is $3.40. Oncternal Therapeutics has a 52-week low of $0.53 and a 52-week high of $13.14. The stock has a market capitalization of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.